The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Leung, Nelson, Bridoux, Frank, Batuman, Vecihi, Chaidos, Aristeidis, Cockwell, Paul, D'Agati, Vivette D, Dispenzieri, Angela, Fervenza, Fernando C, Fermand, Jean-Paul, Gibbs, Simon, Gillmore, Julian D, Herrera, Guillermo A, Jaccard, Arnaud, Jevremovic, Dragan, Kastritis, Efstathios, Kukreti, Vishal, Kyle, Robert A, Lachmann, Helen J, Larsen, Christopher P, Ludwig, Heinz, Markowitz, Glen S, Merlini, Giampaolo, Mollee, Peter, Picken, Maria M, Rajkumar, Vincent S, Royal, Virginie, Sanders, Paul W, Sethi, Sanjeev, Venner, Christopher P, Voorhees, Peter M, Wechalekar, Ashutosh D, Weiss, Brendan M and Nasr, Samih H (2019) The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature reviews. Nephrology, 15 (1). pp. 45-59. ISSN 1759-507X. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

Full text not available from this repository.
Official URL: https://www.nature.com/articles/s41581-018-0077-4#...

Abstract

The term monoclonal gammopathy of renal significance (MGRS) was introduced by the International Kidney and Monoclonal Gammopathy Research Group (IKMG) in 2012. The IKMG met in April 2017 to refine the definition of MGRS and to update the diagnostic criteria for MGRS-related diseases. Accordingly, in this Expert Consensus Document, the IKMG redefines MGRS as a clonal proliferative disorder that produces a nephrotoxic monoclonal immunoglobulin and does not meet previously defined haematological criteria for treatment of a specific malignancy. The diagnosis of MGRS-related disease is established by kidney biopsy and immunofluorescence studies to identify the monotypic immunoglobulin deposits (although these deposits are minimal in patients with either C3 glomerulopathy or thrombotic microangiopathy). Accordingly, the IKMG recommends a kidney biopsy in patients suspected of having MGRS to maximize the chance of correct diagnosis. Serum and urine protein electrophoresis and immunofixation, as well as analyses of serum free light chains, should also be performed to identify the monoclonal immunoglobulin, which helps to establish the diagnosis of MGRS and might also be useful for assessing responses to treatment. Finally, bone marrow aspiration and biopsy should be conducted to identify the lymphoproliferative clone. Flow cytometry can be helpful in identifying small clones. Additional genetic tests and fluorescent in situ hybridization studies are helpful for clonal identification and for generating treatment recommendations. Treatment of MGRS was not addressed at the 2017 IKMG meeting; consequently, this Expert Consensus Document does not include any recommendations for the treatment of patients with MGRS.

Item Type: Article
Additional Information: This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects: WX Health services
Divisions: Emergency Services > Renal
Related URLs:
Depositing User: Jennifer Manders
Date Deposited: 12 Dec 2019 13:36
Last Modified: 12 Dec 2019 13:36
URI: http://www.repository.uhblibrary.co.uk/id/eprint/2681

Actions (login required)

View Item View Item